The company's MOB-015 has been granted patent protection in China, valid until 2032. MOB-015 is an internally developed topical formulation of terbinafine for the treatment of onychomycosis, currently under clinical development in phase 3. MOB-015’s patent protection thus covers the key marketsAlready a subscriber Login You have read all your…